Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMoonLake Immunotherapeutics Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 6 | -$0.95 | -$0.84 | -$0.89 |
| Q2 2026 | 6 | -$0.98 | -$0.83 | -$0.93 |
| Q3 2026 | 6 | -$1.06 | -$0.75 | -$0.94 |
| Q4 2026 | 4 | -$0.93 | -$0.93 | -$0.93 |
| Q1 2027 | 2 | -$1.01 | -$1.01 | -$1.01 |
| Q2 2027 | 2 | -$0.98 | -$0.98 | -$0.98 |
| Q3 2027 | 2 | -$1.02 | -$1.02 | -$1.02 |
| Q4 2027 | 2 | -$0.89 | -$0.89 | -$0.89 |
MoonLake Immunotherapeutics Earnings Date And Information
MoonLake Immunotherapeutics last posted its earnings results on Monday, May 11th, 2026. The company reported $-0.98 earnings per share for the quarter, missing analysts' consensus estimates of $-0.91 by $0.07. The company had revenue of 0 for the quarter and had revenue of 0 for the year. MoonLake Immunotherapeutics has generated $-4 earnings per share over the last year ($-3.53 diluted earnings per share) and currently has a price-to-earnings ratio of -5.71. MoonLake Immunotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
MoonLake Immunotherapeutics Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/11/2026 | Q1 2026 | -$0.91 | -$0.98 | -0.07 | $0 | $0 |
| 02/25/2026 | Q4 2025 | -$0.92 | -$0.93 | -0.01 | $0 | $0 |
| 11/05/2025 | Q3 2025 | -$0.89 | -$1.10 | -0.21 | $0 | $0 |
| 08/05/2025 | Q2 2025 | -$0.73 | -$0.87 | -0.14 | N/A | $0 |
| 05/12/2025 | Q1 2025 | -$0.76 | -$0.63 | 0.13 | N/A | $0 |
| 02/26/2025 | Q4 2024 | -$0.53 | -$0.72 | -0.19 | N/A | $0 |
| 11/07/2024 | Q3 2024 | -$0.44 | -$0.56 | -0.12 | N/A | $0 |
| 08/07/2024 | Q2 2024 | -$0.28 | -$0.39 | -0.11 | N/A | $0 |
| 05/07/2024 | Q1 2024 | -$0.21 | -$0.22 | -0.01 | N/A | $0 |
| 05/07/2024 | Q4 2023 | -$0.21 | -$0.12 | 0.09 | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | -$0.18 | N/A | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.25 | -$0.23 | 0.02 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.28 | -$0.31 | -0.03 | N/A | $0 |
| 03/20/2023 | Q4 2022 | -$0.32 | -$0.05 | 0.27 | N/A | $0 |
| 11/14/2022 | Q3 2022 | -$0.32 | -$0.40 | -0.08 | N/A | $0 |
| 08/12/2022 | Q2 2022 | -$0.54 | -$0.49 | 0.05 | N/A | $0 |
| 05/16/2022 | Q1 2022 | N/A | -$0.43 | N/A | N/A | $0 |
| 02/17/2022 | Q4 2021 | N/A | -$0.06 | N/A | N/A | $0 |
| 11/12/2021 | Q3 2021 | N/A | -$0.17 | N/A | N/A | $0 |
| 08/16/2021 | Q2 2021 | N/A | -$0.89 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
MoonLake Immunotherapeutics Earnings: FAQ's
The conference call for MoonLake Immunotherapeutics's latest earnings report can be listened to online.
The conference call transcript for MoonLake Immunotherapeutics's latest earnings report can be read online.
MoonLake Immunotherapeutics (:MLTX) has a recorded net income of $-227,318,000.MoonLake Immunotherapeutics has generated $-3.53 earnings per share over the last four quarters.
MoonLake Immunotherapeutics (:MLTX) has a price-to-earnings ratio of -5.71 and price/earnings-to-growth ratio is 0.12.